QDEL

A month has gone by since the last earnings report for QuidelOrtho (QDEL). Shares have added about 24.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is QuidelOrtho due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers. QuidelOrtho Corporation delivered adjusted loss per share of 4 cents in first-quarter 2026 against earnings per share of 74 cents in the prior-year quarter. The figure missed the Zacks Consensus Estimate by 110.8%. The adjustments include expenses related to the amortization of intangibles, acquisition and integration costs, among others. GAAP loss per share for the quarter was $1.35 compared with the year-earlier loss of 19 cents. QuidelOrtho registered revenues of $619.8 million in the first quarter of 2026, which decreased 10.5% year over year on a reported basis and 12.6% at constant exchange rate (CER). However, the figure surpassed the Zacks Consensus Estimate by 0.3%. In the first quarter, Respiratory revenues were $67.9 million (down 43.3% on a reported basis and 43.6% at CER), while Non-Respiratory revenues were $551.9 million (down 3.7% on a reported basis and 6.2% at CER). QuidelOrtho derives revenues from five business units — Labs, Immunohematology, Donor Screening, Point of Care and Molecular Diagnostics. As a result of the wind-down of the U.S. Donor Screening portfolio, the previously reported Transfusion Medicine business unit is now presented in its two product categories — Immunohematology and Donor Screening. In the first quarter, Labs revenues were $353.1 million, down 5.3% on a reported basis and 7.6% at CER. Immunohematology revenues were $138.3 million in the first quarter, up 7.6% and 3.4% on a reported basis and at CER, respectively. Donor Screening revenues were $7.8 million in the first quarter, down 39.1% and 39.5% on a reported basis and at CER, respectively. Point of Care revenues amounted to $112.8 million in the first quarter, reflecting a decline of 35%on a reported basis and 34.6% at CER. Molecular Diagnostics revenues totaled $7.8million in the first quarter, up 2.6% and down 1.8% on a reported basis and at CER, respectively. Geographically, QuidelOrtho derives revenues from N...

QuidelOrtho’s first quarter was marked by notable headwinds, as management pointed to a significantly milder and shorter respiratory illness season compared to the prior year and highlighted disruptions in China linked to anticipated changes in diagnostic pricing guidelines. CEO Brian J. Blaser noted, “Our first quarter results were impacted by a significantly softer respiratory season…with influenza-like illness visits down approximately 30%.” Management also cited broader macroeconomic and geopolitical pressures, including order delays in the Middle East, as contributors to the company’s weaker performance. Is now the time to buy QDEL? Find out in our full research report (it’s free). Revenue: $619.8 million vs analyst estimates of $668.7 million (10.5% year-on-year decline, 7.3% miss) Adjusted EPS: -$0.04 vs analyst estimates of $0.36 (significant miss) Adjusted EBITDA: $108.7 million vs analyst estimates of $148.4 million (17.5% margin, 26.7% miss) The company dropped its revenue guidance for the full year to $2.73 billion at the midpoint from $2.8 billion, a 2.7% decrease Management lowered its full-year Adjusted EPS guidance to $1.90 at the midpoint, a 14% decrease EBITDA guidance for the full year is $622.5 million at the midpoint, below analyst estimates of $640.1 million Operating Margin: -5.1%, down from 4.7% in the same quarter last year Constant Currency Revenue fell 12.6% year on year (-1.1% in the same quarter last year) Market Capitalization: $679.2 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Jack Meehan (Jefferies) asked for details on Q2 segment growth and margin outlook. CFO Joseph M. Busky said sequential revenue should remain flat, with year-over-year growth driven by core labs, immunohematology, and triage businesses. Meehan (Jefferies) also pressed for more detail on the China headwind and how much of the guidance reset is tied to market conditions there. Busky explained that guidance was lowered primarily due to weaker respiratory and China sales, with the China impact estimated at $30 million. Andrew Brackmann (William Blair) questioned how QuidelOrtho plans to achieve the implied...

QuidelOrtho Corporation QDEL delivered adjusted loss per share of 4 cents in first-quarter 2026 against earnings per share (EPS) of 74 cents in the prior-year quarter. The figure missed the Zacks Consensus Estimate by 110.8%. The adjustments include expenses related to the amortization of intangibles, acquisition and integration costs, among others. GAAP loss per share for the quarter was $1.35 compared with the year-earlier loss of 19 cents. QuidelOrtho registered revenues of $619.8 million in the first quarter of 2026, which decreased 10.5% year over year on a reported basis and 12.6% at constant exchange rate (CER). However, the figure surpassed the Zacks Consensus Estimate by 0.3%. In the first quarter, Respiratory revenues were $67.9 million (down 43.3% on a reported basis and 43.6% at CER), while Non-Respiratory revenues were $551.9 million (down 3.7% on a reported basis and 6.2% at CER). Shares of the company lost around 6% in yesterday’s trading session. QuidelOrtho derives revenues from five business units — Labs, Immunohematology, Donor Screening, Point of Care and Molecular Diagnostics. As a result of the wind-down of the U.S. Donor Screening portfolio, the previously reported Transfusion Medicine business unit is now presented in its two product categories — Immunohematology and Donor Screening. In the first quarter, Labs revenues were $353.1 million, down 5.3% on a reported basis and 7.6% at CER. Immunohematologyrevenues were $138.3 million in the first quarter, up 7.6% and 3.4% on a reported basis and at CER, respectively. Donor Screening revenues were $7.8 million in the first quarter, down 39.1% and 39.5% on a reported basis and at CER, respectively. Point of Care revenues amounted to $112.8 million in the first quarter, reflecting a decline of 35%on a reported basis and 34.6% at CER. Molecular Diagnosticsrevenues totaled $7.8million in the first quarter, up 2.6% and down 1.8% on a reported basis and at CER, respectively. Geographically, QuidelOrtho derives revenues from North America, Europe, the Middle East and Africa (EMEA), China, Latin America and Japan and other Asia-Pacific markets (JPAC). Revenues from North Americaamounted to $328.9million, reflecting a decline of 19.1% on a reported basis and 18.9% at CER. EMEA revenues amounted to $92.5million, reflecting an increase of 4% on a reported basis and a decline of 6.1% at CER. Revenues...

First quarter performance was significantly impacted by a 30% decline in influenza-like illness (ILI) visits, characterized by a milder and shorter respiratory season compared to 2025. China revenue slowed in March as distributors preemptively reduced inventory purchases in anticipation of upcoming national IVD pricing guidelines. Geopolitical disruption in the Middle East caused delays in certain orders and tenders, though management expects these to resume as conditions stabilize. The acquisition of Lex Diagnostics adds an ultrafast molecular platform to the point-of-care portfolio, targeting customers seeking faster turnaround times and lower costs. Core lab and immunohematology franchises remain durable, with the U.S. launch of high-sensitivity troponin and the VITROS 450 rollout supporting mid-single-digit growth expectations. Management is executing a multi-year margin expansion plan involving the exit of donor screening, facility consolidation in Raritan, and targeted staffing reductions. Full-year 2026 revenue guidance was lowered to $2 billion to $2.75 billion, reflecting Q1 respiratory weakness and estimated impacts from China's draft pricing guidelines. Management assumes an average respiratory season for the second half of 2026, forecasting flat year-over-year performance to remain prudent despite historical rebound trends. The Lex Diagnostics platform is expected to begin placing instruments this quarter, with measurable assay revenue contribution projected to start in early 2027. Despite a negative free cash flow of $67 million in the first quarter, positive free cash flow of $100 million to $120 million is anticipated for the full year, driven by higher expected revenue and seasonal improvements in the second half. China pricing changes are not expected to be fully implemented until mid-2027, providing a window for the company to execute cost-mitigation actions. The termination of the joint business agreement with Grifols created a difficult year-over-year comparison for the labs business in Q1. Inventory levels increased during the quarter due to the weak respiratory season and stockpiling for upcoming product launches. Proposed China pricing changes are expected to impact approximately half of the company's sales in that region once fully implemented. Net debt to adjusted EBITDA leverage stood at 4.1x at quarter-end, with a target to reduce...

Image source: The Motley Fool. May 5, 2026, 5 p.m. ET President and Chief Executive Officer — Brian J. Blaser Chief Financial Officer — Joseph M. Busky Vice President, Investor Relations — Juliet C. Cunningham Need a quote from a Motley Fool analyst? Email [email protected] Juliet C. Cunningham: Afternoon, everyone, and thanks for joining us today. With me are Brian J. Blaser, President and Chief Executive Officer, and Joseph M. Busky, Chief Financial Officer. This conference call is being simultaneously webcast on the Investor Relations page of our website. To assist in the presentation, we also posted supplemental information on our Investor Relations page that will be referenced in this call. This conference call and supplemental information may contain forward-looking statements which are made as of today, 05/05/2026. We assume no obligation to update any forward-looking statement except as required by law. Statements that are not strictly historical, including the company's expectations, plans, financial guidance, future performance, and prospects, are forward-looking statements that are subject to certain risks, uncertainty, assumptions, and other factors. Actual results may vary materially from those expressed or implied in these forward-looking statements. Please refer to our SEC filings for a description of potential risks. In addition, today's call includes discussion of certain non-GAAP financial measures. Tables reconciling these non-GAAP measures to their most directly comparable GAAP measures are available in our earnings release and supplemental information on the Investor Relations page of our website. Lastly, unless stated otherwise, all year-over-year revenue growth rates given on today's call are on a constant currency basis. I will now turn the call over to our CEO, Brian J. Blaser. Brian J. Blaser: Thanks, Juliet, and good afternoon, everyone. I will start today with a brief perspective on the first quarter and then discuss details of our business performance more broadly. Our first quarter results were impacted by a significantly softer respiratory season compared to Q1 of last year, with influenza-like illness, or ILI, visits down approximately 30% as reported by the CDC in April. While ILI visits are one indicator, the season was also notably weaker across other key measures including severity of illness, hospitalizations, and duration. Ove...

― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ― ― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ― ― Company Updates Full-Year 2026 Financial Guidance ― SAN DIEGO, May 5, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026. Key First Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $620 million, as reported Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025. Labs revenue of $353 million declined by 5% as reported and 8% in constant currency, primarily due to slower distributor sales in China that the Company believes is related to pending changes to the China National Health Security Administration ("NHSA") In Vitro Diagnostics ("IVD") pricing guidelines, business disruption related to the Middle East conflict, and a decrease in revenue related in part to the Company's termination of its joint business arrangement with Grifols. Immunohematology revenue of $138 million grew 8% as reported and 3% in constant currency, primarily driven by growth in North America, China and JPAC. GAAP net loss was $92 million; GAAP operating loss was $32 million; adjusted EBITDA was $109 million. GAAP diluted loss per share was $1.35; adjusted diluted loss per share was $0.04. "Our first quarter results were in line with our preliminary revenue announcement and reflected a significantly weaker respiratory season and business disruption in China and the Middle East," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. "Importantly, we believe the underlying business remains strong and we are well positioned to deliver on our objectives to expand our adjusted EBITDA margin and improve cash flow in 2026." "We completed our acquisition of LEX Diagnostics in April, adding an ultra-fast molecular diagnostics platform for point-of-care testing. We also advanced our key strategic priorities, including the U.S. launch of our High-Sensitivity Troponin assay and the rollout of the VITROS 450 platform in select international market...

QuidelOrtho reported Q1 revenue of $620 million with respiratory sales plunging to $68 million, driven by a significantly milder respiratory season (ILI visits down ~30%), cautious Chinese distributors ahead of proposed IVD pricing guidelines, and some Middle East order delays, resulting in negative operating cash flow (-$33M) and free cash flow (-$67M). The company updated 2026 guidance to total revenue of $2.7–$2.75 billion, adjusted EBITDA of $615–$630 million (≈23% margin), adjusted EPS of $1.80–$2.00, and free cash flow of $100–$120 million, expecting a stronger second half and net-debt/EBITDA leverage to fall toward 3.25–3.5x by year-end. Strategic progress includes completing the LEX Diagnostics acquisition for an ultra-fast molecular point-of-care platform with instrument placements beginning this quarter and anticipated assay-driven revenue in early 2027, alongside new product rollouts such as a high-sensitivity troponin assay and the VITROS 450 platform. Interested in QuidelOrtho Corporation? Here are five stocks we like better. Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11 QuidelOrtho (NASDAQ:QDEL) said its first-quarter 2026 results were pressured by a meaningfully weaker respiratory season, distributor caution in China ahead of expected national IVD pricing guidelines, and some order delays tied to Middle East disruptions, while management reiterated expectations for improved profitability and cash generation later in the year. President and CEO Brian Blaser said the quarter was affected by “a significantly softer respiratory season compared to Q1 of last year,” noting influenza-like illness (ILI) visits were down about 30% versus the prior-year period, according to April CDC reporting. He said the season was “notably weaker across other key measures, including severity of illness, hospitalizations, and duration,” calling it both “significantly milder and shorter than in Q1 2025.” → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook Blaser also highlighted macro and geopolitical headwinds. In China, he said sales slowed in March as distributors became cautious ahead of anticipated national IVD pricing guidelines, pausing inventory purchases due to potential future pricing declines. He noted the final guidelines had not been issued following the comment period, and the company’s updated guidance reflects an estima...

SAN DIEGO (AP) — SAN DIEGO (AP) — QuidelOrtho Corporation (QDEL) on Tuesday reported a loss of $91.8 million in its first quarter. The San Diego-based company said it had a loss of $1.35 per share. Losses, adjusted for amortization costs and non-recurring costs, came to 4 cents per share. The medical diagnostics company posted revenue of $619.8 million in the period. QuidelOrtho expects full-year earnings in the range of $1.80 to $2 per share, with revenue in the range of $2.7 billion to $2.75 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on QDEL at https://www.zacks.com/ap/QDEL

Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) will be reporting earnings this Tuesday after market hours. Here’s what you need to know. QuidelOrtho beat analysts’ revenue expectations last quarter, reporting revenues of $723.6 million, up 2.2% year on year. It was a mixed quarter for the company, with a solid beat of analysts’ revenue estimates but a significant miss of analysts’ full-year EPS guidance estimates. Is QuidelOrtho a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, the market is expecting QuidelOrtho’s revenue to decline 3.5% year on year, in line with the 2.6% decrease it recorded in the same quarter last year. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. QuidelOrtho has a history of exceeding Wall Street’s expectations. Looking at QuidelOrtho’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. GE HealthCare delivered year-on-year revenue growth of 7.4%, beating analysts’ expectations by 2.1%, and Intuitive Surgical reported revenues up 23%, topping estimates by 5.8%. GE HealthCare traded down 11.2% following the results while Intuitive Surgical was up 7.2%. Read our full analysis of GE HealthCare’s results here and Intuitive Surgical’s results here. There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 6% on average over the last month. QuidelOrtho is down 21.7% during the same time and is heading into earnings with an average analyst price target of $27 (compared to the current share price of $12.43). ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable. These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.

Wall Street expects a year-over-year decline in earnings on lower revenues when QuidelOrtho (QDEL) reports results for the quarter ended March 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on May 5, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This medical diagnostics company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of -67.6%. Revenues are expected to be $618.07 million, down 10.8% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 58.33% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's p...

SAN DIEGO, April 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenue for the first quarter of 2026, ended March 29, 2026, and provided an update on its full-year 2026 financial guidance. The Company also announced its plan to release its full first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. Preliminary Unaudited First Quarter 2026 Revenue The Company currently expects preliminary unaudited revenue, as reported, of $615-$620 million for the first quarter of 2026. This preliminary unaudited revenue was primarily driven by a weaker respiratory season, with U.S. Influenza-like Illness visits down by approximately 30% compared to the first quarter of 20251, along with slower China distributor sales that the Company believes is related to the proposed China National Health Security Administration ("NHSA") reimbursement rate reductions. Additionally, certain EMEA orders were delayed by the Middle East conflict, negatively impacting first quarter revenue. "Despite macroeconomic challenges and a softer first quarter respiratory season, QuidelOrtho is taking decisive cost actions to drive full-year 2026 performance," said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. "Our core business―representing more than 70% of total revenue―remains strong, providing a solid foundation amid near-term volatility. We remain focused on operational execution, margin expansion, cash flow improvement, and advancing our innovation pipeline to support durable long-term growth." The preliminary unaudited revenue described herein is based on management's preliminary analysis for the first quarter of 2026 and is subject to adjustments based on the Company's completion of its quarter-end financial close process. As discussed in the Company's fourth quarter and full-year 2025 conference call in February 2026, the Company expects free cash flow to be negative for the first half of 2026. The Company currently expects free cash flow to be in the range of $(65) to $(70) million in the first quarter of 2026. The Company continues to expect free cash flow to be positive for the full-year 2026. Full-year 2026 Financial Guidance Based on current information, the Company believes the low end of its full-year 202...